New blood test could end painful liver biopsies for millions

NCT ID NCT04616664

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new blood test called LLIFT to see if it can accurately diagnose fatty liver disease and its severe form, NASH, without needing a liver biopsy. Researchers enrolled 158 people at high risk for metabolic syndrome. The LLIFT test combines patient information like age, weight, and diabetes status with blood markers and genetic data. If proven accurate, this test could make screening for liver disease much easier and safer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LLIFT (Lille LIver Fat Test) – a blood test combining clinical data, lab values, and genetic markers

What this could lead to

If successful, this could provide a simple, non-invasive blood test to diagnose fatty liver disease and NASH, replacing the need for a liver biopsy in many patients.

What could go wrong

This is a diagnostic accuracy study, not a treatment trial. The test may not be accurate enough to replace biopsy in all cases, and results may not apply to lower-risk populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease metabolic syndrome X Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CH ARRAS

    Arras, France

  • CH LENS

    Lens, France

  • CH de Douai

    Douai, France

  • Ch Valenciennes

    Valenciennes, France

  • Chu Amiens Picardie

    Amiens, France

  • GHIRCL saint Philibert

    Lomme, France

  • Hop Claude Huriez Chu Lille

    Lille, 59037, France